1
|
Xi S, Liu H, Zhang J, Hu L, Wang W. Key factors affecting NH 3-N in the Huaihe River Basin due to human activities. ENVIRONMENTAL GEOCHEMISTRY AND HEALTH 2024; 46:218. [PMID: 38849659 DOI: 10.1007/s10653-024-01967-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/10/2024] [Accepted: 03/25/2024] [Indexed: 06/09/2024]
Abstract
Human activity factors have a significant impact on changes in ammonia nitrogen (NH3-N) content in rivers. Existing research mainly focuses on human activity factors as type factors, and lacks research on the key factors affecting river NH3-N among human activity factors. Therefore, this paper aims to study the key factors affecting human activities on NH3-N in the Huaihe River through various statistical analysis methods. The study found that changes in NH3-N content in the Huaihe River are mainly affected by land use patterns in the basin. There are two different ways in which land use affects NH3-N in rivers: direct effects and indirect effects. We also studied the main pathways through which changes in key factors in human activities affect NH3-N in the Huaihe River by constructing a structural equation model. The results showed that crop sowing area and afforestation area have a significant direct effect on NH3-N in the Huaihe River. In addition, crop sowing area and afforestation area can also affect river NH3-N by regulating the amount of nitrogen fertilizer and human excrement. This study is of great significance for understanding how human activities regulate NH3-N content in rivers.
Collapse
Affiliation(s)
- Shanshan Xi
- School of Environmental and Energy Engineering, Anhui Jianzhu University, 292, Ziyun Rd., Shushan District, Hefei City, 230601, Anhui Province, People's Republic of China
- Anhui Provincial Institute of Ecological Civilization, Hefei, Anhui, People's Republic of China
- Anhui Province Tongyuan Environmental Environment Co. Ltd, Hefei, Anhui, People's Republic of China
| | - Hao Liu
- School of Environmental and Energy Engineering, Anhui Jianzhu University, 292, Ziyun Rd., Shushan District, Hefei City, 230601, Anhui Province, People's Republic of China.
- Anhui Provincial Institute of Ecological Civilization, Hefei, Anhui, People's Republic of China.
| | - Jiamei Zhang
- School of Environmental and Energy Engineering, Anhui Jianzhu University, 292, Ziyun Rd., Shushan District, Hefei City, 230601, Anhui Province, People's Republic of China
- Anhui Provincial Institute of Ecological Civilization, Hefei, Anhui, People's Republic of China
| | - Lechang Hu
- School of Environmental and Energy Engineering, Anhui Jianzhu University, 292, Ziyun Rd., Shushan District, Hefei City, 230601, Anhui Province, People's Republic of China
- Anhui Provincial Institute of Ecological Civilization, Hefei, Anhui, People's Republic of China
| | - Wei Wang
- School of Environmental and Energy Engineering, Anhui Jianzhu University, 292, Ziyun Rd., Shushan District, Hefei City, 230601, Anhui Province, People's Republic of China
- Anhui Provincial Institute of Ecological Civilization, Hefei, Anhui, People's Republic of China
| |
Collapse
|
2
|
Kohaar I, Hodges N, Srivastava S. Biomarkers in Cancer Screening: Promises and Challenges in Cancer Early Detection. Hematol Oncol Clin North Am 2024:S0889-8588(24)00046-7. [PMID: 38782647 DOI: 10.1016/j.hoc.2024.04.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/25/2024]
Abstract
Cancer continues to be one the leading causes of death worldwide, primarily due to the late detection of the disease. Cancers detected at early stages may enable more effective intervention of the disease. However, most cancers lack well-established screening procedures except for cancers with an established early asymptomatic phase and clinically validated screening tests. There is a critical need to identify and develop assays/tools in conjunction with imaging approaches for precise screening and detection of the aggressive disease at an early stage. New developments in molecular cancer screening and early detection include germline testing, synthetic biomarkers, and liquid biopsy approaches.
Collapse
Affiliation(s)
- Indu Kohaar
- Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, NIH, 9609 Medical Center Drive, NCI Shady Grove Building, Rockville, MD 20850, USA
| | - Nicholos Hodges
- Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, NIH, 9609 Medical Center Drive, NCI Shady Grove Building, Rockville, MD 20850, USA
| | - Sudhir Srivastava
- Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, NIH, 9609 Medical Center Drive, NCI Shady Grove Building, Rockville, MD 20850, USA.
| |
Collapse
|
3
|
Evin D, Evinová A, Baranovičová E, Šarlinová M, Jurečeková J, Kaplán P, Poláček H, Halašová E, Dušenka R, Briš L, Brožová MK, Sivoňová MK. Integrative Metabolomic Analysis of Serum and Selected Serum Exosomal microRNA in Metastatic Castration-Resistant Prostate Cancer. Int J Mol Sci 2024; 25:2630. [PMID: 38473877 DOI: 10.3390/ijms25052630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2024] [Revised: 02/19/2024] [Accepted: 02/22/2024] [Indexed: 03/14/2024] Open
Abstract
Metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease due to the absence of effective therapies. A more comprehensive understanding of molecular events, encompassing the dysregulation of microRNAs (miRs) and metabolic reprogramming, holds the potential to unveil precise mechanisms underlying mCRPC. This study aims to assess the expression of selected serum exosomal miRs (miR-15a, miR-16, miR-19a-3p, miR-21, and miR-141a-3p) alongside serum metabolomic profiling and their correlation in patients with mCRPC and benign prostate hyperplasia (BPH). Blood serum samples from mCRPC patients (n = 51) and BPH patients (n = 48) underwent metabolome analysis through 1H-NMR spectroscopy. The expression levels of serum exosomal miRs in mCRPC and BPH patients were evaluated using a quantitative real-time polymerase chain reaction (qRT-PCR). The 1H-NMR metabolomics analysis revealed significant alterations in lactate, acetate, citrate, 3-hydroxybutyrate, and branched-chain amino acids (BCAAs, including valine, leucine, and isoleucine) in mCRPC patients compared to BPH patients. MiR-15a, miR-16, miR-19a-3p, and miR-21 exhibited a downregulation of more than twofold in the mCRPC group. Significant correlations were predominantly observed between lactate, citrate, acetate, and miR-15a, miR-16, miR-19a-3p, and miR-21. The importance of integrating metabolome analysis of serum with selected serum exosomal miRs in mCRPC patients has been confirmed, suggesting their potential utility for distinguishing of mCRPC from BPH.
Collapse
Affiliation(s)
- Daniel Evin
- Department of Medical Biochemistry, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 03601 Martin, Slovakia
- Clinic of Nuclear Medicine, Jessenius Faculty of Medicine in Martin, University Hospital in Martin, Comenius University in Bratislava, 03601 Martin, Slovakia
| | - Andrea Evinová
- Biomedical Center Martin, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 03601 Martin, Slovakia
| | - Eva Baranovičová
- Biomedical Center Martin, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 03601 Martin, Slovakia
| | - Miroslava Šarlinová
- Biomedical Center Martin, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 03601 Martin, Slovakia
| | - Jana Jurečeková
- Department of Medical Biochemistry, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 03601 Martin, Slovakia
| | - Peter Kaplán
- Department of Medical Biochemistry, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 03601 Martin, Slovakia
| | - Hubert Poláček
- Clinic of Nuclear Medicine, Jessenius Faculty of Medicine in Martin, University Hospital in Martin, Comenius University in Bratislava, 03601 Martin, Slovakia
| | - Erika Halašová
- Biomedical Center Martin, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 03601 Martin, Slovakia
| | - Róbert Dušenka
- Clinic of Urology, Jessenius Faculty of Medicine in Martin, University Hospital in Martin, Comenius University in Bratislava, 03601 Martin, Slovakia
| | - Lukáš Briš
- Clinic of Urology, Jessenius Faculty of Medicine in Martin, University Hospital in Martin, Comenius University in Bratislava, 03601 Martin, Slovakia
| | - Martina Knoško Brožová
- Department of Medical Biochemistry, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 03601 Martin, Slovakia
| | - Monika Kmeťová Sivoňová
- Department of Medical Biochemistry, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 03601 Martin, Slovakia
| |
Collapse
|
4
|
Wang W, Zhen S, Ping Y, Wang L, Zhang Y. Metabolomic biomarkers in liquid biopsy: accurate cancer diagnosis and prognosis monitoring. Front Oncol 2024; 14:1331215. [PMID: 38384814 PMCID: PMC10879439 DOI: 10.3389/fonc.2024.1331215] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2023] [Accepted: 01/26/2024] [Indexed: 02/23/2024] Open
Abstract
Liquid biopsy, a novel detection method, has recently become an active research area in clinical cancer owing to its unique advantages. Studies on circulating free DNA, circulating tumor cells, and exosomes obtained by liquid biopsy have shown great advances and they have entered clinical practice as new cancer biomarkers. The metabolism of the body is dynamic as cancer originates and progresses. Metabolic abnormalities caused by cancer can be detected in the blood, sputum, urine, and other biological fluids via systemic or local circulation. A considerable number of recent studies have focused on the roles of metabolic molecules in cancer. The purpose of this review is to provide an overview of metabolic markers from various biological fluids in the latest clinical studies, which may contribute to cancer screening and diagnosis, differentiation of cancer typing, grading and staging, and prediction of therapeutic response and prognosis.
Collapse
Affiliation(s)
- Wenqian Wang
- Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
- Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
- Key Laboratory for Tumor Immunology and Biotherapy of Henan Province, Zhengzhou, Henan, China
| | - Shanshan Zhen
- Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
- Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
- Key Laboratory for Tumor Immunology and Biotherapy of Henan Province, Zhengzhou, Henan, China
| | - Yu Ping
- Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
- Key Laboratory for Tumor Immunology and Biotherapy of Henan Province, Zhengzhou, Henan, China
| | - Liping Wang
- Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
| | - Yi Zhang
- Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
- Key Laboratory for Tumor Immunology and Biotherapy of Henan Province, Zhengzhou, Henan, China
- School of Life Sciences, Zhengzhou University, Zhengzhou, Henan, China
- State Key Laboratory of Esophageal Cancer Prevention and Treatment, Zhengzhou University, Zhengzhou, Henan, China
| |
Collapse
|
5
|
Hasubek AL, Wang X, Zhang E, Kobus M, Chen J, Vandergrift LA, Kurreck A, Ehret F, Dinges S, Hohm A, Tilgner M, Buko A, Habbel P, Nowak J, Mercaldo ND, Gusev A, Feldman AS, Cheng LL. Differentiation of patients with and without prostate cancer using urine 1 H NMR metabolomics. MAGNETIC RESONANCE IN CHEMISTRY : MRC 2023; 61:740-747. [PMID: 37654196 DOI: 10.1002/mrc.5391] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/25/2023] [Revised: 08/09/2023] [Accepted: 08/12/2023] [Indexed: 09/02/2023]
Abstract
Prostate cancer (PCa) is one of the most prevalent cancers in men worldwide. For its detection, serum prostate-specific antigen (PSA) screening is commonly used, despite its lack of specificity, high false positive rate, and inability to discriminate indolent from aggressive PCa. Following increases in serum PSA levels, clinicians often conduct prostate biopsies with or without advanced imaging. Nuclear magnetic resonance (NMR)-based metabolomics has proven to be promising for advancing early-detection and elucidation of disease progression, through the discovery and characterization of novel biomarkers. This retrospective study of urine-NMR samples, from prostate biopsy patients with and without PCa, identified several metabolites involved in energy metabolism, amino acid metabolism, and the hippuric acid pathway. Of note, lactate and hippurate-key metabolites involved in cellular proliferation and microbiome effects, respectively-were significantly altered, unveiling widespread metabolomic modifications associated with PCa development. These findings support urine metabolomics profiling as a promising strategy to identify new clinical biomarkers for PCa detection and diagnosis.
Collapse
Affiliation(s)
- Anna-Laura Hasubek
- Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
| | - Xiaoyu Wang
- Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
| | - Ella Zhang
- Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
| | - Marta Kobus
- Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
| | - Jiashang Chen
- Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
| | - Lindsey A Vandergrift
- Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
| | - Annika Kurreck
- Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
| | - Felix Ehret
- Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
| | - Sarah Dinges
- Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
| | - Annika Hohm
- Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
| | - Marlon Tilgner
- Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
| | - Alexander Buko
- Human Metabolome Technologies, Boston, Massachusetts, USA
| | - Piet Habbel
- Charite - Universitatsmedizin Berlin, Berlin, Germany
| | - Johannes Nowak
- SRH Poliklinik Gera GmbH, Radiology Gotha, Gotha, Germany
- SRH University of Applied Health Sciences, Gera, Germany
| | - Nathaniel D Mercaldo
- Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
| | - Andrew Gusev
- Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
| | - Adam S Feldman
- Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
| | - Leo L Cheng
- Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
| |
Collapse
|
6
|
Santorelli L, Caterino M, Costanzo M. Proteomics and Metabolomics in Biomedicine. Int J Mol Sci 2023; 24:16913. [PMID: 38069240 PMCID: PMC10706996 DOI: 10.3390/ijms242316913] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2023] [Accepted: 11/27/2023] [Indexed: 12/18/2023] Open
Abstract
The technological advances of recent years have significantly enhanced medical discoveries [...].
Collapse
Affiliation(s)
- Lucia Santorelli
- Department of Oncology and Hematology-Oncology, University of Milano, 20122 Milan, Italy;
| | - Marianna Caterino
- Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, 80131 Naples, Italy;
- CEINGE–Biotecnologie Avanzate Franco Salvatore, 80145 Naples, Italy
| | - Michele Costanzo
- Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, 80131 Naples, Italy;
- CEINGE–Biotecnologie Avanzate Franco Salvatore, 80145 Naples, Italy
| |
Collapse
|
7
|
Li J, Wang Z, Liu W, Tan L, Yu Y, Liu D, Wei Z, Zhang S. Identification of metabolic biomarkers for diagnosis of epithelial ovarian cancer using internal extraction electrospray ionization mass spectrometry (iEESI-MS). Cancer Biomark 2023:CBM220250. [PMID: 37248885 DOI: 10.3233/cbm-220250] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
BACKGROUND Epithelial ovarian cancer (EOC) is the leading cause of death from gynecologic malignancies. The poor prognosis of EOC is mainly due to its asymptomatic early stage, lack of effective screening methods, and a late diagnosis in the advanced stages of the disease. OBJECTIVE This study investigated metabolomic abnormalities in epithelial ovarian cancers. METHODS Our study developed a novel strategy to rapidly identify the metabolic biomarkers in the plasma of the EOC patients using Internal Extraction Electrospray Ionization Mass Spectrometry (IEESI-MS) and Liquid Chromatography-mass Spectrometry (HPLC-MS), which could distinguish the differential metabolites in between plasma samples collected from 98 patients with epithelial ovarian cancer, including 78 cases with original (P), and 20 cases with self-configuration (ZP), as well as 60 healthy subjects, including 30 cases in the original sample (H), 30 cases in self-configuration (ZH), and 6 cases in a blind sample (B). RESULTS Our study detected 880 metabolites based on criteria variable importance in projection (VIP) > 1, among which 26 metabolites were selected for further identification. They are mainly metabolism-related lipids, amino acids, nucleic acids, and others. The metabolic pathways associated with the differential metabolites were explored by the KEGG analysis, a comprehensive database that integrates genome, chemistry, and system function information. The abnormal metabolites of EOC patients identified by IEESI-MS and HPLC-MS included Lysophosphatidylcholine (16:0) [Lyso PC (16:0)], L-Phenylalanine, L-Leucine, Phenylpyruvic acid, L-Tryptophan, and L-Histidine. CONCLUSIONS Identifying the abnormal metabolites of EOC patients through metabolomics analyses could provide a new strategy to identify valuable potential biomarkers for the screening and early diagnosis of EOC.
Collapse
Affiliation(s)
- Jiajia Li
- Department of Gynecologic Oncology, The First Hospital of Jilin University, Changchun, Jilin, China
- Department of Gynecologic Oncology, The First Hospital of Jilin University, Changchun, Jilin, China
| | - Zhenpeng Wang
- Department of Gynecologic Oncology, The First Hospital of Jilin University, Changchun, Jilin, China
- Department of Gynecologic Oncology, The First Hospital of Jilin University, Changchun, Jilin, China
| | - Wenjie Liu
- Weiming Environmental Molecular Diagnostics (Changshu) Co.Ltd. Changshun, Jilin, China
- College of New Energy and Environment, Key Lab of Groundwater Resource and Environment Ministry of Education, Jilin University, Changchun, Jilin, China
| | - Linsheng Tan
- Department of Gynecologic Oncology, The First Hospital of Jilin University, Changchun, Jilin, China
| | - Yunhe Yu
- Department of Gynecologic Oncology, The First Hospital of Jilin University, Changchun, Jilin, China
| | - Dongzhen Liu
- Department of Gynecologic Oncology, The First Hospital of Jilin University, Changchun, Jilin, China
| | - Zhentong Wei
- Department of Gynecologic Oncology, The First Hospital of Jilin University, Changchun, Jilin, China
| | - Songling Zhang
- Department of Gynecologic Oncology, The First Hospital of Jilin University, Changchun, Jilin, China
| |
Collapse
|
8
|
Song G, Wang L, Tang J, Li H, Pang S, Li Y, Liu L, Hu J. Circulating metabolites as potential biomarkers for the early detection and prognosis surveillance of gastrointestinal cancers. Metabolomics 2023; 19:36. [PMID: 37014438 PMCID: PMC10073066 DOI: 10.1007/s11306-023-02002-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/30/2022] [Accepted: 03/22/2023] [Indexed: 04/05/2023]
Abstract
BACKGROUND AND AIMS Two of the most lethal gastrointestinal (GI) cancers, gastric cancer (GC) and colon cancer (CC), are ranked in the top five cancers that cause deaths worldwide. Most GI cancer deaths can be reduced by earlier detection and more appropriate medical treatment. Unlike the current "gold standard" techniques, non-invasive and highly sensitive screening tests are required for GI cancer diagnosis. Here, we explored the potential of metabolomics for GI cancer detection and the classification of tissue-of-origin, and even the prognosis management. METHODS Plasma samples from 37 gastric cancer (GC), 17 colon cancer (CC), and 27 non-cancer (NC) patients were prepared for metabolomics and lipidomics analysis by three MS-based platforms. Univariate, multivariate, and clustering analyses were used for selecting significant metabolic features. ROC curve analysis was based on a series of different binary classifications as well as the true-positive rate (sensitivity) and the false-positive rate (1-specificity). RESULTS GI cancers exhibited obvious metabolic perturbation compared with benign diseases. The differentiated metabolites of gastric cancer (GC) and colon cancer (CC) were targeted to same pathways but with different degrees of cellular metabolism reprogramming. The cancer-specific metabolites distinguished the malignant and benign, and classified the cancer types. We also applied this test to before- and after-surgery samples, wherein surgical resection significantly altered the blood-metabolic patterns. There were 15 metabolites significantly altered in GC and CC patients who underwent surgical treatment, and partly returned to normal conditions. CONCLUSION Blood-based metabolomics analysis is an efficient strategy for GI cancer screening, especially for malignant and benign diagnoses. The cancer-specific metabolic patterns process the potential for classifying tissue-of-origin in multi-cancer screening. Besides, the circulating metabolites for prognosis management of GI cancer is a promising area of research.
Collapse
Affiliation(s)
- Guodong Song
- The Second Hospital of Tianjin Medical University, No 23. Pingjiang Road, Hexi District, 300211, Tianjin, China
| | - Li Wang
- The Second Hospital of Tianjin Medical University, No 23. Pingjiang Road, Hexi District, 300211, Tianjin, China
| | - Junlong Tang
- Metanotitia Inc, No 59. Gaoxin South 9Th Road, Yuehai Street, Nanshan District, Shenzhen, 518056, Guangdong, China
| | - Haohui Li
- Metanotitia Inc, No 59. Gaoxin South 9Th Road, Yuehai Street, Nanshan District, Shenzhen, 518056, Guangdong, China
| | - Shuyu Pang
- Metanotitia Inc, No 59. Gaoxin South 9Th Road, Yuehai Street, Nanshan District, Shenzhen, 518056, Guangdong, China
| | - Yan Li
- Metanotitia Inc, No 59. Gaoxin South 9Th Road, Yuehai Street, Nanshan District, Shenzhen, 518056, Guangdong, China
| | - Li Liu
- Metanotitia Inc, No 59. Gaoxin South 9Th Road, Yuehai Street, Nanshan District, Shenzhen, 518056, Guangdong, China.
| | - Junyuan Hu
- Metanotitia Inc, No 59. Gaoxin South 9Th Road, Yuehai Street, Nanshan District, Shenzhen, 518056, Guangdong, China.
| |
Collapse
|
9
|
Xu B, Gao W, Xu T, Liu C, Wu D, Tang W. A UPLC Q-Exactive Orbitrap Mass Spectrometry-Based Metabolomic Study of Serum and Tumor Tissue in Patients with Papillary Thyroid Cancer. TOXICS 2022; 11:44. [PMID: 36668770 PMCID: PMC9863332 DOI: 10.3390/toxics11010044] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 12/02/2022] [Revised: 12/20/2022] [Accepted: 12/27/2022] [Indexed: 06/17/2023]
Abstract
OBJECTIVE To find the metabolomic characteristics of tumor or para-tumor tissues, and the differences in serums from papillary thyroid cancer (PTC) patients with or without lymph node metastasis. METHODS We collected serums of PTC patients with/without lymph node metastasis (SN1/SN0), tumor and adjacent tumor tissues of PTC patients with lymph node metastasis (TN1 and PN1), and without lymph node metastasis (TN0 and PN0). Metabolite detection was performed by ultra-high performance liquid chromatography combined with Q-Exactive orbitrap mass spectrometry (UPLC Q-Exactive). RESULTS There were 31, 15, differential metabolites in the comparisons of TN1 and PN1, TN0 and PN0, respectively. Seven uniquely increased metabolites and fourteen uniquely decreased metabolites appeared in the lymph node metastasis (TN1 and PN1) group. Meanwhile, the results indicated that four pathways were co-owned pathways in two comparisons (TN1 and PN1, TN0 and PN0), and four unique pathways presented in the lymph node metastasis (TN1 and PN1) group. CONCLUSIONS Common or differential metabolites and metabolic pathways were detected in the lymph node metastasis and non-metastatic group, which might provide novel ways for the diagnosis and treatment of PTC.
Collapse
Affiliation(s)
- Bo Xu
- State Key Laboratory of Reproductive Medicine, School of Public Health, Nanjing Medical University, Nanjing 211166, China
| | - Wei Gao
- Department of Endocrinology, Nanjing Medical University Affiliated Geriatric Hospital, Nanjing 210024, China
| | - Ting Xu
- Department of Endocrinology, Nanjing Medical University Affiliated Geriatric Hospital, Nanjing 210024, China
| | - Cuiping Liu
- Bank of Biological Samples, First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
| | - Dan Wu
- Department of Endocrinology, Nanjing Medical University Affiliated Geriatric Hospital, Nanjing 210024, China
| | - Wei Tang
- Department of Endocrinology, Nanjing Medical University Affiliated Geriatric Hospital, Nanjing 210024, China
| |
Collapse
|